KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $1.35.

  • Jazz Pharmaceuticals' Debt to Equity fell 758.38% to $1.35 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.35, marking a year-over-year decrease of 758.38%. This contributed to the annual value of $1.49 for FY2024, which is 239.2% down from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Debt to Equity of $1.35 as of Q3 2025, which was down 758.38% from $1.45 recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Debt to Equity registered a high of $2.09 during Q3 2022, and its lowest value of $0.55 during Q1 2021.
  • Over the past 5 years, Jazz Pharmaceuticals' median Debt to Equity value was $1.54 (recorded in 2024), while the average stood at $1.55.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Debt to Equity soared by 20165.47% in 2022, and later plummeted by 2148.57% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Debt to Equity (Quarter) stood at $1.53 in 2021, then grew by 21.58% to $1.86 in 2022, then dropped by 17.59% to $1.53 in 2023, then dropped by 2.39% to $1.49 in 2024, then fell by 9.25% to $1.35 in 2025.
  • Its Debt to Equity was $1.35 in Q3 2025, compared to $1.45 in Q2 2025 and $1.29 in Q1 2025.